Following Randall Steward’s last QDEL Sell transaction on December 14, 2017, the stock climbed by 21.2%.
Based on Quidel Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $117 million and quarterly net profit of $10.82 million. In comparison, last year the company earned revenue of $50.89 million and had a GAAP net loss of $5.53 million. QDEL’s market cap is $2.39B and the company has a P/E ratio of 68.07. Currently, Quidel Corp has an average volume of 453.7K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $77.67, reflecting a 26.7% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular diagnostics, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.